This trial is evaluating whether Pembrolizumab will improve 1 primary outcome and 6 secondary outcomes in patients with Hodgkin Disease. Measurement will happen over the course of Up to approximately 9 weeks.
This trial requires 140 total participants across 1 different treatment group
This trial involves a single treatment. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The incidence of NHL is increasing; however, the rates remain stable among all demographic groups. Data from a recent study suggest that increased awareness and early detection may contribute to the rise in NHL incidence." - Anonymous Online Contributor
"The median age of diagnosis of HL is 68 years (mean 61.3), with a range of 28 to 90 years. Median age at death from HL is 72 years (mean 70.7) with a range of 30 to 94 years. There were no significant differences in age at diagnosis or death between males and females." - Anonymous Online Contributor
"Based on these results, we believe that pembrolizumab has a role in the treatment of refractory or recurrent HL. However, further phase III studies will need to address optimal dosing schedules and mechanisms of resistance." - Anonymous Online Contributor
"Although one family history of lymphoma has been reported, its presence is not indicative of familial inheritance of lymphoma. No evidence was found that any of the families had a hereditary predisposition to lymphoma, nor was a significant difference seen in the age at onset between families with a positive family history and those without a family history (P > 0.05)." - Anonymous Online Contributor
"Pembrolizumab is a monoclonal antibody specific for the PD-1 receptor. In clinical trials, it has demonstrated antitumor efficacy against multiple cancer types including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), squamous cell carcinoma of head and neck (SCCHN), and Merkel-cell carcinoma. It is approved by the FDA for treatment of patients with metastatic melanoma who have failed previous treatments and are not candidates for surgery or radiotherapy." - Anonymous Online Contributor
"Pembrolizumab is safe and effective in the treatment of patients with advanced NHL. Patients treated with pembrolizumab had a significant improvement in their symptoms and duration of remission when compared with patients treated with rituximab or CHOP alone. The median time to disease progression was 8.3 months in patients treated with pembrolizumab versus 6.4 months in patients treated with CHOP alone. Survival data are awaited. Clinicaltrials.gov ID: NCT00557145." - Anonymous Online Contributor
"Pembrolizumab appears effective in the treatment of patients with advanced solid tumors. Although our results are encouraging, larger, prospective studies are needed to confirm these findings." - Anonymous Online Contributor
"Although the results showed that there is no correlation between pathological findings and clinical manifestations in patients with localized diffuse large B-cell lymphoma, we recommend fixation of specimens and sending them to labs for immunohistochemical studies to investigate whether a relationship exists between histological features and clinical presentation." - Anonymous Online Contributor
"In this review, only one randomized controlled trial had been published (without blinding). It seems likely that most patients who receive pembrolizumab will be unable to generate meaningful data because they will not know if they received the drug or placebo. Overall, there is little evidence of benefit from pembrolizumab and no evidence of harm. Although more data on long term efficacy is needed, current information suggests that pembrolizumab may be useful in treating relapsed or refractory disease. Patients should be informed that although pembrolizumab has shown promise in a few rare cases, they are unlikely to experience a durable response to treatment with this agent." - Anonymous Online Contributor
"Survival rates for most types of lymphoma are very high; however, with some types of lymphoma such as mantle cell lymphoma and diffuse large B-cell lymphoma, those diagnosed with stage IV disease have poor outcomes. These patients usually receive standard chemotherapy regimens that do not appear to improve their overall survival compared with patients treated with observation alone. Patients with early or advanced stage Hodgkin's lymphoma have better outcomes. There may be additional benefits of chemotherapy in treating Hodgkin's lymphoma but further research needs to be conducted to determine these outcomes." - Anonymous Online Contributor
"The most common adverse reactions in patients treated with pembrolizumab were fatigue, fever, nausea, rash, and itchiness. There were no serious adverse events reported in patients treated with pembrolizumab. An increase in liver enzymes and hyperglycemia were also observed, although they did not appear to be clinically significant. Patients treated with pembrolizumab should be closely monitored during treatment and throughout their follow-up period for symptoms associated with increased risk of infection and autoimmune disorders. Pembrolizumab does not appear to have negative effects on fertility. A child born to a woman who received pembrolizumab while pregnant has been reported." - Anonymous Online Contributor